Protagonist Therapeutics (PTGX) Research & Development (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Research & Development data on file, last reported at $46.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 30.22% year-over-year to $46.7 million; the trailing twelve-month figure through Mar 2026 stood at $170.1 million (up 21.28% YoY), and the FY2025 full-year result was $159.3 million, up 15.32% from the prior year.
• Research & Development climbed to $46.7 million in Q1 2026, from $46.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $46.7 million in Q1 2026 to a low of $25.4 million in Q3 2022.
• A 5-year average of $34.7 million and a median of $34.6 million in 2022 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 49.8% in 2022, while the deepest fall reached 31.26% in 2022.
• Tracing PTGX's Research & Development over 5 years: stood at $29.9 million in 2022, then slipped by 3.3% to $28.9 million in 2023, then increased by 20.78% to $34.9 million in 2024, then soared by 32.82% to $46.4 million in 2025, then gained by 0.82% to $46.7 million in 2026.
• Business Quant data shows PTGX's Research & Development at $46.7 million in Q1 2026, $46.4 million in Q4 2025, and $40.0 million in Q3 2025.